News Column

Researchers from Sapienza University Detail New Studies and Findings in the Area of Cardiology (Serum and supplement optimization for EU...

June 30, 2014



Researchers from Sapienza University Detail New Studies and Findings in the Area of Cardiology (Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture)

By a News Reporter-Staff News Editor at Clinical Trials Week -- Fresh data on Cardiology are presented in a new report. According to news reporting out of Latina, Italy, by NewsRx editors, research stated, "Cardiac progenitor cells (CPCs) isolated as cardiospheres (CSs) and CS-derived cells (CDCs) are a promising tool for cardiac cell therapy in heart failure patients, having CDCs already been used in a phase I/II clinical trial. Culture standardization according to Good Manufacturing Practices (GMPs) is a mandatory step for clinical translation."

Our news journalists obtained a quote from the research from Sapienza University, "One of the main issues raised is the use of xenogenic additives (e.g. FBS, foetal bovine serum) in cell culture media, which carries the risk of contamination with infectious viral/prion agents, and the possible induction of immunizing effects in the final recipient. In this study, B27 supplement and sera requirements to comply with European GMPs were investigated in CSs and CDCs cultures, in terms of process yield/efficiency and final cell product gene expression levels, as well as phenotype. B27-free CS cultures produced a significantly reduced yield and a 10-fold drop in c-kit expression levels versus B27+ media. Moreover, autologous human serum (aHS) and two different commercially available GMP AB HSs were compared with standard research-grade FBS. CPCs from all HSs explants had reduced growth rate, assumed a senescent-like morphology with time in culture, and/or displayed a significant shift towards the endothelial phenotype. Among three different GMP gamma-irradiated FBSs (giFBSs) tested, two provided unsatisfactory cell yields, while one performed optimally, in terms of CPCs yield/phenotype."

According to the news editors, the research concluded: "The use of HSs for the isolation and expansion of CSs/CDCs has to be excluded because of altered proliferation and/or commitment, while media supplemented with B27 and the selected giFBS allows successful EU GMP-complying CPCs culture."

For more information on this research see: Serum and supplement optimization for EU GMP-compliance in cardiospheres cell culture. Journal of Cellular and Molecular Medicine, 2014;18(4):624-34. Journal of Cellular and Molecular Medicine can be contacted at: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA. (Wiley-Blackwell - www.wiley.com/; Journal of Cellular and Molecular Medicine - onlinelibrary.wiley.com/journal/10.1111/(ISSN)1582-4934)

Our news journalists report that additional information may be obtained by contacting I. Chimenti, Dept. of Medical Surgical Sciences and Biotechnology, Sapienza University of Rome, Latina, Italy. Additional authors for this research include R. Gaetani, E. Forte, F. Angelini, E. De Falco, G.B. Zoccai, E. Messina, G. Frati and A. Giacomello (see also Cardiology).

Publisher contact information for the Journal of Cellular and Molecular Medicine is: Blackwell Publishing Inc, 350 Main St, Malden, MA 02148, USA.

Keywords for this news article include: Italy, Latina, Europe, Cardiology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Clinical Trials Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters